January 26, 2024 BY Elizabeth Anderson
Impact of weight loss drugs on medical devices and food and beverage stocks waning
Sales of Novo Nordisk’s (NVO) diabetic drug, Ozempic, escalated by more than $1bn between its $2.3bn in Q3 2022 and $3.5bn in Q3 2023. Yahoo Finance noticed the absence of any discussions around GLP-1s at two conferences. A JPMorgan analyst, who attended a healthcare conference in January 2024, viewed this as good news for the…
Read more